Comparative Efficacies of Amlodipine-Telmisartan Versus Cilnidipine-Telmisartan in the Management of Hypertension

Abstract

Background: Hypertension is a common cardiovascular issue that necessitates efficient pharmacological management to avoid complications. Calcium channel blockers together with angiotensin receptor blockers are frequently recommended. This research sought to evaluate the effectiveness of Amlodipine-Telmisartan compared to Cilnidipine-Telmisartan in treating hypertension.

Methods: A total of 100 patients with hypertension were recruited and evenly split into two groups. Group A was administered Amlodipine-Telmisartan, while Group B was given Cilnidipine-Telmisartan. Baseline and post-treatment metrics such as systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate, pulse rate, and body mass index (BMI) were assessed. Statistical analysis was performed on the data to compare the treatment outcomes.

Results: The age group most frequently affected was 56-60 years in both categories. The average baseline SBP was comparable between Group A (166.34 mmHg) and Group B (166.46 mmHg), with reductions after treatment to 130.72 mmHg and 128.14 mmHg, respectively. DBP reduced from 93.16 mmHg to 79.18 mmHg in Group A and from 97.52 mmHg to 80.7 mmHg in Group B. Although the decreases in SBP and DBP were not statistically significant (p = 0.18 and p = 0.17), Group B exhibited a statistically significant heart rate reduction (p = 0.00).

Conclusion: Amlodipine-Telmisartan and Cilnidipine-Telmisartan are both effective in reducing blood pressure. Cilnidipine-Telmisartan showed a notably greater decrease in heart rate, likely resulting from its effect on both L-type and N-type calcium channels. This renders it a favored option for hypertensive patients needing heart rate regulation. Additional long-term research is suggested to assess the enduring cardiovascular advantages of these combinations.